DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/vww5fg/renal_anemia) has announced the addition of the "Renal Anemia - Pipeline Review, H2 2013" report to their offering.
'Renal Anemia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Renal Anemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Renal Anemia.
Scope
- A snapshot of the global therapeutic scenario for Renal Anemia.
- A review of the Renal Anemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Renal Anemia pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Companies Mentioned
Hospira, Inc.
Medgenics Inc.
Amgen Inc.
GlaxoSmithKline plc
FibroGen, Inc.
Reliance Life Sciences Pvt. Ltd.
Dong-A Pharmaceutical Co., Ltd.
Japan Tobacco Inc.
Zydus Cadila Healthcare Limited
Bayer AG
Zosano Pharma, Inc.
3SBio Inc.
Zenotech Laboratories Limited
ProMetic Life Sciences Inc.
JCR Pharmaceuticals Co., Ltd.
CCM Duopharma Biotech Bhd.
Uni-Bio Science Group Ltd.
Panacea Biotec Limited
Affymax, Inc.
Acceleron Pharma, Inc.
Pieris AG
For more information visit http://www.researchandmarkets.com/research/vww5fg/renal_anemia
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
